Tango is moving toward late-stage development of vopimetostat with daraxonrasib in pancreatic cancer after early combination data, while holding $1.0 billion in cash.
Dr. Barbara Weber's employment as Executive Chair ended August 3, 2026, and Tango filed an 8-K/A on August 7 detailing the severance terms of her exit.
